Literature DB >> 802925

Deep vein thrombosis treated with streptokinase or heparin. Follow-up of a randomized study.

H H Common1, A J Seaman, J Rösch, J M Porter, C T Dotter.   

Abstract

Twenty-seven patients with deep vein thrombosis whose primary therapy was randomized between streptokinase and heparin were reevaluated clinically and by ascending venography after a mean period of 7 months. Normal venograms were found in 6 (40%) of the streptokinase-treated patients and in 1 patient (8%) who had heparin therapy. Segmental valve preservation was found in 1 patient from each group. All patients with complete or partial valve preservation became asymptomatic. Vein recanalization without preservation of valves occurred in 18 patients: 8 (54%) of those on streptokinase, and 10 (83%) of those on heparin. At the time of follow-up, 11 of these 18 patients, including 8 who had had prior thrombosis, reported peripheral edema; the postphlebitic syndrome developed in 1. Factors favoring a good outcome of acute venous thrombosis were (1) no prior thrombotic disease, (2) localized thrombosis, and (3) prompt streptokinase therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 802925     DOI: 10.1177/000331977602701105

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  12 in total

Review 1.  Use of plasminogen activators in venous thrombosis.

Authors:  J Hirsh; A G Turpie
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Mechanical interventions and thrombolytic therapy in venous thrombosis and pulmonary embolism.

Authors:  Rajesh Subramanian; Christopher J White
Journal:  Ochsner J       Date:  2002

Review 4.  Thrombolysis for acute deep vein thrombosis.

Authors:  Lorna Watson; Cathryn Broderick; Matthew P Armon
Journal:  Cochrane Database Syst Rev       Date:  2016-11-10

5.  Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis.

Authors:  Ariel Izcovich; Juan M Criniti; Federico Popoff; Liming Lu; Jiaming Wu; Walter Ageno; Daniel M Witt; Michael R Jaff; Sam Schulman; Veena Manja; Peter Verhamme; Gabriel Rada; Yuqing Zhang; Robby Nieuwlaat; Wojtek Wiercioch; Holger J Schünemann; Ignacio Neumann
Journal:  Blood Adv       Date:  2020-04-14

6.  [Fibrinolytic therapy of lower limb deep vein thrombosis with urokinase (author's transl)].

Authors:  R Zimmermann; J Harenberg; H Mörl; H M Kuhn; P Wahl; P Gerhardt
Journal:  Klin Wochenschr       Date:  1982-05-17

Review 7.  Use of thrombolytic drugs in non-coronary disorders.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

8.  Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb.

Authors:  Cathryn Broderick; Lorna Watson; Matthew P Armon
Journal:  Cochrane Database Syst Rev       Date:  2021-01-19

Review 9.  [Fibrinolytic therapy of deep vein thrombosis].

Authors:  B Weidmann; W Jansen; B Franzen; M Tauchert
Journal:  Med Klin (Munich)       Date:  1999-03-15

10.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang
Journal:  Blood Adv       Date:  2020-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.